The ISPOR Best Contributed Podium and Poster Presentation Awards were established in 1998 to recognize the scientific merit of podium and poster presentations of the ISPOR Annual International Meetings, Annual European Congresses, and Asia-Pacific Conferences. At this year’s International Meeting,
This year, the ISPOR Research Award judges evaluated 72 podium presentations and over 100 nominated poster presentations. All podium presentations are considered for an award. Poster presentations in the top 20%, based on abstract review score, are considered and eligible for a poster presentation award.
Evaluations of scientific merit were based upon the following criteria:

Background provides appropriate perspective / context for the subject
Objectives / research questions are clearly stated
Research design / methods / modeling is appropriate and transparent (scores on this will determine winners in case of ties)
Data sources and/or sampling procedures are clear and appropriate
Data analyses are appropriate
Research objectives are met/addressed
Implications of findings are discussed
Factual information is kept separate from interpretations or implications
Abstract is presented in an unbiased manner
Clarity of presentation

A special thanks goes to Rajesh Balkrishnan PhD, MS, Chair, ISPOR Contributed Research Paper Awards Committee -- Podium Presentations, AS WELL AS TO Judith Shinogle PhD, MSc, Chair, ISPOR Contributed Research Paper Awards Committee -- Poster Presentations, for all their efforts in selecting the winners!

THE RECIPIENTS ARE: . . .

ISPOR Best Contributed Paper Awards Podium Presentations

Best General Podium Presentations

	AC7-COMPARING ADHERENCE TO FIXED DOSE COMBINATION VERSUS MULTI-PILL COMBINATION THERAPIES AMONG PATIENTS WITH DYSLIPIDEMIA IN A MANAGED CARE POPULATION Balu S1, Simko RJ1, Burge RT1, Quimbo R2, Cziraky MJ2 1Abbott Laboratories, Abbott Park, IL, USA, 2HealthCore, Inc, Wilmington, DE, USA
	AC8 - ASSOCIATION OF MEASURES OF MEDICATION ADHERENCE AND SEVERE RELAPSES WITH MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPY Dickson M1, Kozma C2, Okuda DT3, Fincher C4, Meletiche D4 1University of South Carolina, College of Pharmacy, Columbia, SC, USA, 2University of South Carolina, West Columbia, SC, USA, 3University of California, San Francisco, San Francisco, CA, USA, 4EMD Serono, Inc, Rockland, MA, USA Drug Use Research II
	PR3 - IMPACT OF UNCONTROLLED PEDIATRIC ASTHMA ON HEALTH-RELATED QUALITY OF LIFE (HRQOL) Dean BB1, Calimlim B1, Aguilar D1, Sacco P2, Maykut R2, Tinkelman D3 1Cerner LifeSciences, Beverly Hills, CA, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, National Jewish Medical and Research Center, Denver, CO, USA

Best New Investigator Podium Presentations

	CN2-ECONOMIC EVALUATION OF EGFR-GUIDED TREATMENT IN ADVANCED REFRACTORY NON SMALL-CELL LUNG CANCER Carlson JJ1, Garrison L1, Ramsey S2, Veenstra DL1 1University of Washington, Seattle, WA, USA, 2Fred Hutchinson Cancer Research Center, Seattle, WA, USA
	CN4 - COSTS ASSOCIATED WITH NEUTROPENIA IN ELDERLY PATIENTS TREATED FIRST-LINE FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) Stokes ME1, Muehlenbein CE2, Marciniak MD2, Faries D2, Motabar S3, Buesching DP2, Gillespie TW4, Lipscomb J4, Knopf KB5 1United BioSource Corporation, Dorval, QC, Canada, 2Eli Lilly and Company, Indianapolis, IN, USA, 3United BioSource, Bethesda, MD, USA, 4Emory University and Veterans Affairs Medical Center, Atlanta, GA, USA, 5California Pacific Medical Center, San Francsico, CA, USA
	MD1 - MEDICARE PART D: EARLY EVIDENCE ON PRESCRIPTION DRUG TREATMENT PATTERNS, HOSPITALIZATION OFFSETS AND MEDICARE SPENDING Zhang Y1, Newhouse JP2, Hanlon J1, Lave J1, Donohue JM1 1University of Pittsburgh, Pittsburgh, PA, USA, 2Harvard University, Boston, MA, USA

Best Student Podium Presentations

	CA3 - A COST-EFFECTIVENESS ANALYSIS OF HEPATITIS C SCREENING AMONG IMMIGRANTS IN CANADA Chen W1, Dinner K2, Wong T2, Heathcote J3, Krahn MD3 1University of Toronto, Toronto, ON, Canada, 2Public Health Agency of Canada, Ottawa, ON, Canada, 3University Health Network, Toronto, ON, Canada
	MD2 - THE IMPACT OF MEDICARE PART D ON THE PERCENT GROSS MARGIN EARNED BY TEXAS INDEPENDENT PHARMACIES FOR DUAL ELIGIBLE BENEFICIARY CLAIMS Winegar AL, Shepherd MD, Lawson K, Richards KM University of Texas at Austin, Austin, TX, USA
	PM1- RASCH RATING SCALE ANALYSIS OF THE EQ-5D USING THE 2003 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) Gu NY, Doctor JN University of Southern California, Los Angeles, CA, USA

ISPOR Best Contributed Paper Awards Poster Presentation

Best General Poster Presentations

	PHP62 - HOW EVIDENCE-BASED AND TIMELY ARE MEDICARE COVERAGE DECISIONS FOR NEW TECHNOLOGIES: AN EMPIRICAL ANALYSIS, 1999-2007 Kamae M, Palmer JA, Neumann PJ Tufts-New England Medical Center, Boston, MA, USA
	PMH47 - THE RELATIONSHIP BETWEEN THE ANTIPSYCHOTIC MEDICATION ADHERENCE AND PATIENT OUTCOMES AMONG BIPOLAR DISORDER PATIENTS Lage MJ1, Hassan M2 1HealthMetrics Outcomes Research, LLC, Groton, CT, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
	PSY14 - ECONOMIC EVALUATION OF LENOLIDOMIDE USE FOR MULTIPLE MYELOMA IN SCOTLAND IN PATIENTS WHO HAVE RECEIVED ONE PRIOR THERAPY Deniz B1, Ishak KJ2, Shearer A3, Dale P4, Caro JJ1 1United BioSource Corporation, Concord, MA, USA, 2United BioSource Corporation, Montreal, QC, Canada, 3Celgene Corporation, Windsor, UK, 4United Biosource, London, England, UK

Best New Investigator Poster Presentations

	PMH46 - PREDICTORS OF MEDICATION ADHERENCE AMONG SCHIZOPHRENIA PATIENTS TREATED WITH CONVENTIONAL AND ATYPICAL ANTIPSYCHOTICS IN A LARGE STATE MEDICAID PROGRAM Lee SP1, Lang K2, Jackel J2, Crivera C3, Dirani RG4, Menzin J5 1Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 2Boston Health Economics, Inc, Waltham, MA, USA, 3Ortho-McNeil Janssen Scientific Affairs, L.L.C, Titusville, NJ, USA, 4Ortho-McNeil Janssen Scientific Affairs, Titusville, NJ, USA, 5Boston Health Economics, Waltham, MA, USA
	PMH66 - ETHNICITY AND THE IMPACT OF HIGHER MEDICATION COPAYMENTS AMONG VETERANS WITH SCHIZOPHRENIA Zeber JE1, Copeland LA1, Miller AL2, Kilbourne AM3, Velligan DI2, Mortensen EM2 1Veterans Affairs HSRD / UTHSCSA, San Antonio, TX, USA, 2UTHSCSA, San Antonio, TX, USA, 3Veterans Affairs HSRD / University of Michigan, Ann Arbor, MI, USA
	PND46 - THE RISKS OF MULTIPLE GENERIC SUBSTITUTION OF ANTIEPILEPTIC DRUGS : THE CASE OF TOPIRAMATE Lelorier J1, Duh MS2, Paradis PE3, Latremouille-Viau D4, Sheehy O5, Greenberg P2, Lee SP6, Rupnow MF7 1Universite de Montreal, Montreal, QC, Canada, 2Analysis Group, Inc, Boston, MA, USA, 3Groupe d'analyse, Ltd, Montreal, QC, Canada, 4Groupe d'analyse, Ltee, Montreal, QC, Canada, 5Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 6Ortho McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA, 7Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USA

Best Student Poster Presentations

	PCV72-ENHANCING THE EFFECTIVENESS OF COMMUNITY STROKE RISK SCREENING: A RANDOMIZED CONTROL TRIAL Anderson RT1, Camacho F1, Kharbanda A2, Iaconi A2, Balkrishnan R3 1Wake Forest University School of Medicine, Winston Salem, NC, USA, 2The Ohio State University, Columbus, OH, USA, 3The Ohio State University College of Pharmacy, Columbus, OH, USA
	PMH14 - DIFFERENTIAL EFFECTS OF OLANZAPINE AND CLOZAPINE ON TYPE II DIABETES: FINDINGS FROM A CLAIMS DATABASE Donga PZ, Pandey GS, Chen H University of Houston, Houston, TX, USA
	PMH15 - ANALYSIS OF POTENTIAL DRUG-DRUG INTERACTION PAIRS ASSOCIATED WITH ANTIPSYCHOTICS AMONG MEDICAID PATIENTS WITH SCHIZOPHRENIA OR BIPOLAR DISORDER Jing Y1, Guo JJ1, Patel NC2, Kelton CM1, Fan H3, Keck P1 1University of Cincinnati, Cincinnati, OH, USA, 2University of Georgia, Augusta, GA, USA, 3Covance Inc, Sun Prairie, WI, USA

ISPOR would like to thank all the judges who have volunteered their time and efforts during the meeting to score podium and poster presentations.